NEWS AND PUBLICATIONS

News

11/28/2012
Galenea’s MANTRA™ System and Pro-Cognitive Program Selected as One of the Top 10 Neuroscience Projects to Watch by Elsevier Business Intelligence

09/06/2012
Galenea Awarded $3 Million NIH Grant to Develop Translational EEG Biomarkers for Schizophrenia

08/09/2012
Galenea and CHDI Foundation Announce Extension and Expansion of Huntington's Disease Collaboration

07/16/2012
Timothy A. Ryan, PhD Joins Galenea’s Scientific Advisory Board

07/10/2012
Galenea and Eisai Enter into Research Collaboration to Develop Synaptic Modulators for Neurodegenerative Diseases

04/26/2012
Galenea to Receive $6 Million from The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program

10/06/2011
Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function

09/28/2011
Galenea Awarded Two SBIR Grants to Advance Innovative Approaches for the Discovery and Development of Effective Treatments for Schizophrenia

09/06/2011
Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease

10/14/2010
Galenea Awarded $4.5 Million Grant for Advancement of Innovative Synaptic Transmission Screen

12/01/2009
Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration

10/06/2009
Galenea Awarded RC1 Challenge Grant to Develop Predictive In Vivo Models of Cognition

10/28/2008
Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity

10/06/2008
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration

05/21/2007
Galenea Corp. Appoints Mark Benjamin as Chief Executive Officer

04/07/2006
Galenea To Focus On Development Of CNS Drugs

02/23/2006
Nastech Pharmaceutical Company Inc. (NSTK) Acquires RNAi Therapeutics Program Targeting Influenza From Galenea

11/17/2005
Galenea Corp. Awarded Phase I SBIR To Develop siRNA Products for Prevention and Treatment of Influenza Infection

02/16/2005
Galenea Corp. Signs Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd.

Publications

Chan, B, Cottrell, JR, Li, B, Larson, KC, Ashford, CJ, Levenson, JM, Laeng, P, Gerber, DJ, and Song, J. (2013) Development of a High-Throughput AlphaScreen Assay for Modulators of Synapsin I Phosphorylation in Primary Neurons. J Biomol Screen, 10.1177/1087057113505905.

Cottrell JR, Levenson JM, Kim SH, Gibson HE, Richardson KA, Sivula M, Li B, Ashford CJ, Heindl KA, Babcock RJ, Rose DM, Hempel CM, Wiig KA, Laeng P, Levin ME, Ryan TA, and Gerber DJ. (2013) Working Memory Impairment in Calcineurin Knock-out Mice Is Associated with Alterations in Synaptic Vesicle Cycling and Disruption of High-Frequency Synaptic and Network Activity in Prefrontal Cortex. JNeurosci, 33(27):10938-49

Levenson, JM, Cottrell, JR, Richardson, KA, Hempel, CM, Buerger, ED, Sirianni, AC, Mann, JJ, Eschle, BK, Lee, R, Yhorling, GJ, Beaumont, V, Levin, ME, Gerber, DJ. (2012) Alterations of presynaptic function and oscillatory activity in cortex of Huntington's disease models. 7th Annual Huntington's Disease Therapeutics Conference, Palm Springs, CA.

Laeng, P, Hempel, CM, Mann, JJ, Cottrell, JR, and Gerber, DJ. (2012) Optimization of neuronal cultures derived from human induced pluripotent stem cells for high throughput assays of synaptic function. Stem Cells for Drug Developers, Boston, MA.

Hempel, CM, Sivula, MS, Levenson, JM, Rose, DM, Li, B, Sirianni, AC, Xia, E, Ryan, TA, Gerber, DJ, and Cottrell, JR. (2011) A system for performing high throughput assays of synaptic function. PLoS ONE, 6(10): e25999. doi:10.1371/ journal.pone.0025999

Cottrell, JR, Li, B, and Gerber, DJ. (2006) Calcineurin A gamma is expressed in the brain and forms a functional phosphatase. Program No. 588.24. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.

Gogos, JA and Gerber, DJ. (2006) Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends in Pharmacological Sciences, 27(4):226-233.

Miyakawa, T et al. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. PNAS, 100(15):8987-92.

Gerber, DJ et al. (2003) Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. PNAS, 100(15):8993-8.

Zeng, H et al. (2001) Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell, 107(5):617-629.